These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 17520238

  • 1. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [Abstract] [Full Text] [Related]

  • 2. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [Abstract] [Full Text] [Related]

  • 3. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA.
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [Abstract] [Full Text] [Related]

  • 4. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M.
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [Abstract] [Full Text] [Related]

  • 5. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 6. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
    Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F.
    Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
    [Abstract] [Full Text] [Related]

  • 7. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.
    Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA.
    Diabetologia; 2009 Apr; 52(4):723-32. PubMed ID: 19169664
    [Abstract] [Full Text] [Related]

  • 8. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [Abstract] [Full Text] [Related]

  • 9. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
    Samadfam R, Awori M, Bénardeau A, Bauss F, Sebokova E, Wright M, Smith SY.
    J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
    [Abstract] [Full Text] [Related]

  • 10. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 11. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [Abstract] [Full Text] [Related]

  • 12. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA, Bahgat AK, Saleh S.
    Eur J Pharmacol; 2016 Feb 15; 773():59-70. PubMed ID: 26825546
    [Abstract] [Full Text] [Related]

  • 13. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.
    Mol Endocrinol; 2005 Jun 15; 19(6):1593-605. PubMed ID: 15831517
    [Abstract] [Full Text] [Related]

  • 14. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
    Coletta DK, Fernandez M, Cersosimo E, Gastaldelli A, Musi N, DeFronzo RA.
    Diabet Med; 2015 May 15; 32(5):657-64. PubMed ID: 25484175
    [Abstract] [Full Text] [Related]

  • 15. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M, H6E-MC-GLAT study group.
    Clin Ther; 2005 May 15; 27(5):554-67. PubMed ID: 15978304
    [Abstract] [Full Text] [Related]

  • 16. Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR2 in coronary arteries and coronary VSMCs.
    Shen X, Li H, Li W, Wu X, Ding X.
    Mol Cell Endocrinol; 2012 Nov 05; 363(1-2):27-35. PubMed ID: 22820128
    [Abstract] [Full Text] [Related]

  • 17. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun 05; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 18. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
    Black RN, Ennis CN, Young IS, Hunter SJ, Atkinson AB, Bell PM.
    J Diabetes Complications; 2014 Jun 05; 28(3):323-7. PubMed ID: 24560135
    [Abstract] [Full Text] [Related]

  • 19. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
    Rasouli N, Kern PA, Elbein SC, Sharma NK, Das SK.
    Pharmacogenet Genomics; 2012 Jul 05; 22(7):484-97. PubMed ID: 22437669
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist.
    Ninomiya H, Hirata A, Kozawa J, Nakata S, Kimura T, Kitamura T, Yasuda T, Otsuki M, Imagawa A, Kaneto H, Funahashi T, Shimomura I.
    Intern Med; 2016 Jul 05; 55(9):1143-7. PubMed ID: 27150869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.